Cairo, Egypt — MSD Egypt presented groundbreaking findings from its TRIPOLI study at the 17th Breast Gynecological & Immuno-oncology International Cancer Conference (BGICC 2025) in Cairo. The TRIPOLI study, the first of its kind in the Middle East and North Africa (MENA) region, explores the challenges and current treatments for triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer. The study marks a significant step in advancing cancer care across the Arab region.
The findings were unveiled at a press briefing attended by leading oncology experts, highlighting the critical role of early detection, diagnosis, and treatment strategies for TNBC. The TRIPOLI study emphasizes the effectiveness of neoadjuvant treatments, aiming to improve patient outcomes in the MENA region.
Dr. Hazem Abdel Samie, Managing Director of MSD Egypt Cluster, emphasized the importance of early diagnosis, stating, “Early detection is vital for better outcomes, as patients diagnosed at earlier stages have significantly improved chances of survival. We are committed to supporting cancer patients and advancing treatment options in collaboration with healthcare stakeholders.”
Professor Hamdy Abdel Azim, Professor of Clinical Oncology at Cairo University, underscored the need for innovation and access to advanced treatments, especially in underserved areas. He stated, “Advanced-stage TNBC requires novel therapeutic strategies and better access to care. The study’s outcomes can help shape future healthcare strategies to improve outcomes in MENA.”
The TRIPOLI study, involving 702 newly diagnosed TNBC patients from nine Arab countries, provides valuable insights into treatment outcomes and the impact of early diagnosis. It reinforces the necessity of early-stage interventions, effective treatment regimens, and personalized therapeutic approaches to improve survival rates, particularly in high-risk cases.
Key findings from the study highlight: Early detection is crucial for better survival outcomes in TNBC patients.
Innovation and improved access to care are essential for advanced-stage TNBC.
Collaboration among healthcare providers, policymakers, and stakeholders is necessary to ensure equitable access to treatment.
Additionally, a health economic analysis conducted in Egypt concluded that innovative treatments for early-stage TNBC can meet cost-effectiveness thresholds, offering promising implications for the country’s healthcare system.
The TRIPOLI study’s findings are expected to shape future oncology practices and cancer care strategies, emphasizing the importance of collaboration in advancing care for TNBC patients across the MENA region.
https://tnmn.tv/
